Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126604021 | 12660402 | 1 | I | 20160805 | 20160802 | 20160817 | 20160817 | EXP | US-VALIDUS PHARMACEUTICALS LLC-US-2016VAL002451 | VALIDUS | 74.13 | YR | F | Y | 0.00000 | 20160817 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126604021 | 12660402 | 1 | PS | LASIX | FUROSEMIDE | 1 | Oral | 20 MG, QD | 16273 | 20 | MG | TABLET | |||||||
| 126604021 | 12660402 | 2 | SS | REVATIO | SILDENAFIL CITRATE | 1 | 20 MG, TID | 0 | 20 | MG | |||||||||
| 126604021 | 12660402 | 3 | SS | HYDROCODONE | HYDROCODONE | 1 | 325 MG, PRN | N | 0 | 325 | MG | ||||||||
| 126604021 | 12660402 | 4 | SS | K-LOR | POTASSIUM CHLORIDE | 1 | UNK, BID | 0 | TABLET | ||||||||||
| 126604021 | 12660402 | 5 | C | MIRAPEX | PRAMIPEXOLE DIHYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 126604021 | 12660402 | 6 | C | NEURONTIN | GABAPENTIN | 1 | UNK | 0 | |||||||||||
| 126604021 | 12660402 | 7 | C | ADVAIR HFA | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | UNK | 0 | |||||||||||
| 126604021 | 12660402 | 8 | C | PLAQUENIL | HYDROXYCHLOROQUINE SULFATE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126604021 | 12660402 | 1 | Peripheral swelling |
| 126604021 | 12660402 | 2 | Pulmonary hypertension |
| 126604021 | 12660402 | 3 | Spinal operation |
| 126604021 | 12660402 | 4 | Peripheral swelling |
| 126604021 | 12660402 | 5 | Product used for unknown indication |
| 126604021 | 12660402 | 6 | Product used for unknown indication |
| 126604021 | 12660402 | 7 | Product used for unknown indication |
| 126604021 | 12660402 | 8 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126604021 | 12660402 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126604021 | 12660402 | Constipation | |
| 126604021 | 12660402 | Flatulence | |
| 126604021 | 12660402 | Intestinal perforation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126604021 | 12660402 | 1 | 2015 | 0 | ||
| 126604021 | 12660402 | 2 | 2015 | 0 | ||
| 126604021 | 12660402 | 3 | 20160805 | 0 |